NeuroFirst Memory
Commercial- Indications
- Alzheimer's Disease
Company intelligence / Profile preview
Cx Precision Medicine has developed and commercialized blood-based diagnostic tests—most notably the NeuroFirst™ Memory test—for early detection and differentiation of neurodegenerative diseases such as Alzheimer’s dementia. Their technology leverages large-scale proteomic analysis combined with artificial intelligence to provide actionable results for primary care physicians. The company is recognized for its evidence-based approach and has joined initiatives like StartUp Health's Alzheimer's Moonshot community. Clinical validation data supports improved accuracy in ruling out or identifying patients who may benefit from further neurological evaluation.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cx Precision Medicine.